Selinexor (XPOVIO™) is a first-in-class, oral, small molecule Exportin-1 (XPO1) inhibitor that
is being developed by Karyopharm Therapeutics for the treatment of cancer. Selinexor (in …

Multiple myeloma (MM) is one the most common hematological malignancies, and despite
the survival prolongation offered by proteasome inhibitors (PIs), immunomodulatory drugs …

Nuclear export proteins such as exportin-1 (XPO1) transport tumor-suppressor proteins and
other growth-regulatory proteins from the nucleus to the cytoplasm. Overexpression of XPO1 …

Introduction Selinexor, an XPO1 inhibitor, has emerged as a promising therapeutic option in
the challenging landscape of relapsed/refractory multiple myeloma (RRMM). Areas covered …

With the incorporation of novel agents in earlier lines of therapy, an increasing number of
multiple myeloma patients are refractory to traditional classes of drugs. Selinexor in …

Over the last 20 years, breakthroughs in accessible therapies for the treatment of multiple
myeloma (MM) have been made. Nevertheless, patients with MM resistant to …

Objectives Multiple myeloma (MM) remains an incurable disease despite advances in
treatment options. Recently, selinexor has shown promising efficacy for relapsed/refractory …

Although the survival rate of patients with multiple myeloma has significantly improved in the
last years thanks to the introduction of various classes of new drugs, such as proteasome …

Introduction: Selinexor, an XPO1 inhibitor, has emerged as a promising therapeutic option in
the challenging landscape of relapsed/refractory multiple myeloma (RRMM). Areas covered …

Exportin 1 (XPO1) is a crucial molecule of nucleocytoplasmic transport. Among others, it
exports molecules important for oncogenesis from the nucleus to the cytoplasm. The …